The war of generics

Our Bureau Mumbai | Updated on March 22, 2011

Cut-throat competition is fast commoditising the erstwhile ‘highly specialised' pharmaceutical industry said market experts. There is huge global one-upmanship going on in the field of generics, they said.

Everyone wants to have his way on any drug that is going off-patent. The latest in the in list to feel the heat is Ranbaxy. “The big fish in the pharma industry worldwide are trying to eat away the smaller ones in order to grow,” said an industry expert.

“The frightening thing about this is the methods used are totally unethical in many cases,” he added. If companies are not able to buy out smaller players there have been instances of complaining to the FDA about players not following USFDA prescribed good manufacturing practices or even trying to buy out key personnel and ensure that the FDA approval of the smaller player is jeopardised.

Published on March 22, 2011

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like